Medicare will still cover Avastin for breast cancer, despite revocation of FDA approval

March 18, 2017

The Washington Post: FDA Revokes Avastin's Approval For Breast Cancer Treatment The case has triggered strong reactions from advocates of easier access to new treatments and from critics fearing health-care rationing. It is also being seen as one of the most visible medical examples of scientific evidence winning out over an animated public outcry. ... Avastin costs about $99,000 a year per patient (Stein, 11/18).

Friday afternoon's summary of Avastin coverage: FDA Revokes Approval Of Avastin For Breast Cancer.

This article was reprinted from kaiserhealthnews with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.